Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SI | P14410 | 1/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.43 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CAD | P27708 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL764895 | 1.00 | ALDH1A1 (0.48) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL15034672 | 1.00 | ALDH1A1 (0.48) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL12640198 | 0.88 | ALDH1A1 (0.53) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL19318891 | 0.88 | ALDH1A1 (0.53) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL6767176 | 0.84 | ALDH1A1 (0.43) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL12328387 | 0.83 | ALDH1A1 (0.48) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL13269391 | 0.82 | ALDH1A1 (0.42) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL22267821 | 0.82 | ABCB1 (0.45) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL6591829 | 0.81 | ALDH1A1 (0.46) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL10411232 | 0.81 | ALDH1A1 (0.46) | ALDH1A1LMNAHSD17B10ALOX15MGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119985872-A | Sweet potato brandy flavor analysis method | 烟台大学 | 2025-05-13 | — | — | CN | disclosed |
| US-20250066361-A1 | 5,6,7,7a-Tetrahydrocyclopenta[f]pyrido[1,2-h][1,7] naphthyridin-11(4bH)-one Compounds and Methods of use Use (as amended) | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-02-27 | — | — | US | disclosed |
| US-12221444-B2 | 5,6,7,7a-tetrahydrocyclopenta[f]pyrido[1,2-h][1,7]naphthyridin-11(4bH)-one compounds and methods of use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-02-11 | — | — | US | disclosed |
| CN-111801833-B | Nonaqueous electrolyte and energy device using same | 三菱化学株式会社 | 2024-07-16 | — | — | CN | disclosed |
| CN-118119615-A | Solid forms of Rho-associated protein kinase inhibitors or solvates thereof, methods of making and uses thereof | 北京泰德制药股份有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-111788733-B | Nonaqueous electrolyte and power storage device using same | 三菱化学株式会社 | 2024-02-02 | — | — | CN | disclosed |
| US-20230357207-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | BCP3 PTY LIMITED (AU) | 2023-11-09 | — | — | US | disclosed |
| CN-116942663-A | Compounds for the treatment of HBV | 葛兰素史克知识产权开发有限公司 | 2023-10-27 | — | — | CN | disclosed |
| US-11795135-B2 | Prostacyclin compounds, compositions and methods of use thereof | INSMED INCORPORATED (US) | 2023-10-24 | — | — | US | disclosed |
| US-11780844-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-7399782-B2 | Polyether brevetoxin derivatives as a treatment for cystic fibrosis, mucociliary dysfunction, and pulmonary diseases | UNIVERSITY OF NORTH CAROLINA AT WILMINGTON (US) | 2008-07-15 | — | — | US | disclosed |
| CN-100401400-C | Rewritable optical information recording medium and recording/reproducing method, recording/reproducing device | SONY CORP MITSUI CHEMICALS INC (JP) | 2008-07-09 | — | — | CN | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| WO-2007062308-A2 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070117797-A1 | Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2007-05-24 | — | — | US | disclosed |
| CN-1646325-A | Rewritable optical information recording medium and recording/reproducing method, recording/reproducing device | SONY CORP MITSUI CHEMICALS INC (JP) | 2005-07-27 | — | — | CN | disclosed |
| EP-1141044-A1 | SOLID CATALYST COMPONENT FOR OLEFIN POLYMERIZATION, CATALYST FOR OLEFIN POLYMERIZATION AND PROCESS FOR PRODUCING OLEFIN POLYMER | Basell Technology Company B.V. (NL) | 2001-10-10 | — | — | EP | disclosed |
| WO-2001036496-A1 | SOLID CATALYST COMPONENT FOR OLEFIN POLYMERIZATION, CATALYST FOR OLEFIN POLYMERIZATION AND PROCESS FOR PRODUCING OLEFIN POLYMER | BASELL TECHNOLOGY COMPANY B.V. (NL) | 2001-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780844-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, OAT | ALDH1A1 1784/4885LMNA 1800/4885HSD17B10 3389/4885 |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | ALDH1A1 2353/4885LMNA 170/4885HSD17B10 255/4885 |
| US-20070117797-A1 | Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity | CCR7, ACKR3, CCR2 | ALDH1A1 1954/4885LMNA 4599/4885HSD17B10 2559/4885 |
| US-12221444-B2 | 5,6,7,7a-tetrahydrocyclopenta[f]pyrido[1,2-h][1,7]naphthyridin-11(4bH)-one compounds and methods of use | HAVCR2, HBS1L, HBG1 | ALDH1A1 1568/4885LMNA 384/4885HSD17B10 2027/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | ALDH1A1 2353/4885LMNA 170/4885HSD17B10 255/4885 |
| US-20250066361-A1 | 5,6,7,7a-Tetrahydrocyclopenta[f]pyrido[1,2-h][1,7] naphthyridin-11(4bH)-one Compounds and Methods of use Use (as amended) | HAVCR2, HMBS, HBS1L | ALDH1A1 749/4885LMNA 655/4885HSD17B10 1327/4885 |
| US-20230357207-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | MUC1, MPO, SERPINB1 | ALDH1A1 489/4885LMNA 1999/4885HSD17B10 330/4885 |
| US-11795135-B2 | Prostacyclin compounds, compositions and methods of use thereof | PTGIS, PTGIR, PTGER1 | ALDH1A1 2360/4885LMNA 762/4885HSD17B10 1755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.